(Q54522784)

30 May 2018

title

Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma. (English)

1 reference

30 May 2018

0 references

1 reference

Sarita B Bagadi

1

1 reference

30 May 2018

Meera Sanghvi

series ordinal

2

1 reference

30 May 2018

Sudish B Nair

series ordinal

3

1 reference

30 May 2018

Bibhu R Das

series ordinal

4

1 reference

30 May 2018

publication date

1 January 2012

1 reference

30 May 2018

The International Journal of Biological Markers

published in

1 reference

30 May 2018

volume

27

1 reference

30 May 2018

issue

1

1 reference

30 May 2018

page(s)

27-33

1 reference

30 May 2018

Global cancer statistics, 2002

cites work

1 reference

https://api.crossref.org/works/10.5301%2FJBM.2012.9108

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.5301%2FJBM.2012.9108

KRAS mutations predict response to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.5301%2FJBM.2012.9108

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.5301%2FJBM.2012.9108

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.5301%2FJBM.2012.9108

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.5301%2FJBM.2012.9108

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.5301%2FJBM.2012.9108

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.5301%2FJBM.2012.9108

Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.5301%2FJBM.2012.9108

PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.5301%2FJBM.2012.9108

BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.5301%2FJBM.2012.9108

Frequency and spectrum of K-RAS codons 12 and 13 mutations in colorectal adenocarcinomas from Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.5301%2FJBM.2012.9108

NRAS mutations are rare in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.5301%2FJBM.2012.9108

Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.5301%2FJBM.2012.9108

Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA).

21 January 2018

1 reference

https://api.crossref.org/works/10.5301%2FJBM.2012.9108

p53 and K-ras gene mutations in carcinoma of the rectum among Finnish women

21 January 2018

1 reference

https://api.crossref.org/works/10.5301%2FJBM.2012.9108

Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.5301%2FJBM.2012.9108

The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.5301%2FJBM.2012.9108

Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes

21 January 2018

1 reference

https://api.crossref.org/works/10.5301%2FJBM.2012.9108

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.5301%2FJBM.2012.9108

The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.5301%2FJBM.2012.9108

Detection of BRAF mutations in colorectal tumours and peritoneal washings using a mismatch ligation assay

21 January 2018

1 reference

https://api.crossref.org/works/10.5301%2FJBM.2012.9108

K-ras point mutations in human colorectal carcinomas: relation to aneuploidy and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.5301%2FJBM.2012.9108

KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.5301%2FJBM.2012.9108

Colorectal cancer molecular biology moves into clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.5301%2FJBM.2012.9108

21 January 2018

Identifiers

DOI

10.5301/JBM.2012.9108

1 reference

30 May 2018

PubMed ID

22427190

1 reference

30 May 2018